MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway
Related Experiment Video
Updated: Mar 28, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
Kai Huang1, Yuxin Tang1, Leye He1
1Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.
Abstract:
An increasing number of studies have demonstrated the important role of microRNAs (miRNAs) in modulating cancer progression and metastasis, but the mechanisms by which miRNAs regulate prostate cancer (PCa) tumorigenesis remain poorly understood. In the present study, we found that miR-340 may act as a tumor suppressor based on our finding that it was significantly downregulated in PCa tumor tissues and cell lines. Moreover, the expression of miR-340 was found to be correlated with the inhibition of cell proliferation, migration and invasion in vitro, and had a suppressive effect on tumor growth in a xenograft mouse model as well. The suppressive effect of miR-340 overexpression was observed in cell lines DU145 and BPH-1 which express wild-type (WT) p53. However, in the p53-null PC-3 cell line, the suppressive effect was not found, indicating that miR-340 may play a critical role in the p53 pathway. Further investigation revealed that mouse double minute 2 (MDM2), an important regulator of p53, was targeted by miR-340 through the direct binding to the 3'UTR of MDM2, which inhibited MDM2 translation. In addition, miR-340 expression stabilized p53 protein levels which caused an increase in p21 expression but a decrease in the anti‑apoptotic protein, BCL-2, in the p53 WT cell lines. Moreover, the miR-340-mediated inhibition of cell progression was mitigated by re-expressing MDM2 in the stable miR‑340-overexpressing PCa cell line, which harbors WT p53. Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa.
Insights
MicroRNA-340 (miR-340) acts as a tumor suppressor in prostate cancer (PCa) by downregulating MDM2, stabilizing p53, and inhibiting tumor growth. This suggests miR-340 is a potential target for novel PCa therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) play a role in cancer progression, but their specific mechanisms in prostate cancer (PCa) are not fully understood.
- Understanding miRNA regulation is crucial for developing targeted therapies for PCa.
Purpose of the Study:
- To investigate the role of miR-340 in prostate cancer (PCa) tumorigenesis.
- To elucidate the molecular mechanisms underlying miR-340's function in PCa.
Main Methods:
- Quantitative analysis of miR-340 expression in PCa tissues and cell lines.
- In vitro assays for cell proliferation, migration, and invasion.
- In vivo xenograft mouse model for tumor growth assessment.
- Western blotting and luciferase reporter assays to confirm target interaction and pathway analysis.
Main Results:
- miR-340 was significantly downregulated in PCa tissues and cell lines.
- Overexpression of miR-340 inhibited PCa cell proliferation, migration, invasion, and tumor growth.
- miR-340 directly targets MDM2, inhibiting its translation and stabilizing p53.
- miR-340 overexpression led to increased p21 and decreased BCL-2 in p53 wild-type cells.
Conclusions:
- miR-340 functions as a tumor suppressor in PCa by targeting the MDM2-p53 pathway.
- miR-340's regulatory role in PCa highlights its potential as a therapeutic target.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Drugs that Stabilize Microtubules

